Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01424956 · ClinicalTrials.gov registry record

CRRS-4 Pivotal Somo•v™ ABUS ROC Reader Observer Study

A clinical trial of Breast Cancer, sponsored by U-Systems.

Completed
Registry status
17
Enrollment target
1
Study location

NCT01424956: Completed study of Breast Cancer, sponsored by U-Systems.

NCT01424956 is a study of Breast Cancer that has completed, run by U-Systems. The registered enrollment target is 17 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01424956, a study of Breast Cancer, has completed, sponsored by U-Systems.

COMPLETED
Registry status
17 participants
Enrollment target
1
Study location

Study Summary

To determine the impact on Interpreting Physician performance in detecting breast cancer, as defined by the area under the Receiver Operating Characteristic Curve (ROC), when Automated Breast Ultrasound (ABUS) and screening mammography (XRM) are combined, compared to screening mammography alone in asymptomatic women with \>50% parenchymal density and a screening mammogram assigned a BI-RADS Assessment Category 1 (negative) or 2 (normal with benign findings). The effect of the improved Reader performance is illustrated by plotting the ROC curves for XRM alone and XRM+ABUS. If Reader performance improves with the addition of ABUS to the XRM, the area under the curve (AUC) for XRM+ABUS (AUCXRM+ABUS) will be greater than the area under the curve for XRM Alone (AUCXRM Alone). This difference is represented as ∆AUCABUS. The null and alternative hypotheses can be formally expressed as follows: H0: ∆AUCABUS = 0, AUCXRM+ABUS = AUCXRM Alone The null hypothesis is that Reader performance will be unchanged with the addition of ABUS to a screening mammogram assigned a BI-RADS Assessment Category of 1 or 2. HA: ∆AUCABUS ≠ 0, AUCXRM+ABUS ≠ AUCXRM Alone The alternative hypothesis is that Reader performance will be changed with the addition of ABUS to a screening mammogram assigned a BI-RADS Assessment Category of 1 or 2. A statistically significant change will be considered equivalent to a statistically significant improvement if the estimated value of AUCXRM+ABUS is greater than that of AUCXRM Alone with statistical significance at an alpha level of .05 for a two-sided test.

Conditions Studied

Interventions

  • DEVICE Automated Breast Ultrasound (ABUS)

Study Locations (1)

California

  • U-Systems, Inc. - Sunnyvale

Trial Details

FieldValue
Enrollment Target 17 participants
Start Date 2011-07
Est. Completion 2011-09

Sponsor

U-Systems

2 total trials

What the Registry Record Tells You About NCT01424956

The ClinicalTrials.gov registry entry for NCT01424956 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The listed sponsor is U-Systems, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Automated Breast Ultrasound (ABUS) is the first listed.

NCT01424956 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT01424956 about?

NCT01424956 is a clinical study titled "CRRS-4 Pivotal Somo•v™ ABUS ROC Reader Observer Study". To determine the impact on Interpreting Physician performance in detecting breast cancer, as defined by the area under the Receiver Operating Characteristic Curve (ROC), when Automated Breast Ultrasound (ABUS) and screening mammography (XRM) are combined, compared to screening mammography alone in a...

What is the current status of trial NCT01424956?

This trial is currently completed. The enrollment target is 17 participants. The study started on 2011-07. Estimated completion is 2011-09.

What conditions does trial NCT01424956 study?

This clinical trial studies the following conditions: Breast Cancer.

What interventions are being tested in trial NCT01424956?

The interventions under investigation include: Automated Breast Ultrasound (ABUS) (DEVICE).

Who is sponsoring clinical trial NCT01424956?

This trial is sponsored by U-Systems, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01424956 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.